Literature DB >> 29680993

Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case-control study design and a traditional case-control study design.

Takahisa Kimiya1, Masayoshi Shinjoh2, Makoto Anzo3, Hiroki Takahashi3, Shinichiro Sekiguchi2, Norio Sugaya4, Takao Takahashi2.   

Abstract

Both traditional case-control studies (TCCSs) and test-negative case-control studies (TNCCSs) are commonly used to assess influenza vaccine effectiveness (VE). To compensate for the fact that observational studies are susceptible to bias, we combined both methods to assess VE in one geographical area during the 2015/2016 season, when influenza A (H1N1)pdm was dominant. Our TNCCS covered 331 children aged 6 months to 15 years who visited our hospital with fever, including 182 with influenza, and our TCCS covered 812 pediatric outpatients aged 6 months to 15 years, including 214 with influenza. Influenza infection and vaccination history were reviewed, and VE was calculated as (1 - odds ratio) × 100. In the TNCCS, VE against influenza A was 68% (95% CI 47-81) overall, and 70% (48-83) for those given two doses; against influenza B, VE was 37% (- 12-64) overall and 49% (2-74) for two doses. In the TCCS, VE against influenza A was 44% (15-63) overall and 44% (13-64) for two doses, and VE against influenza B was 24% (- 19-52) overall and 41% (3-64) for two doses.
CONCLUSION: Both studies confirmed significant VE against influenza A, significant two-dose VE against influenza B, and better two-dose VE than one-dose VE. What is Known: • Influenza vaccine effectiveness (VE) varies from year to year. • Observational studies are conventionally used for VE assessment. However, they are inherently susceptible to bias and confounding. What is New: • This is the first report of influenza VE assessment using more than one observational study and performed in a specific area during the same season. • VE estimates obtained in our traditional case-control study were lower than those in our test-negative case-control study, but both studies found significant VE against influenza.

Entities:  

Keywords:  2015/2016 season; Inactivated quadrivalent influenza vaccine; Influenza vaccine effectiveness; Test-negative case-control study; Traditional case-control study

Mesh:

Substances:

Year:  2018        PMID: 29680993     DOI: 10.1007/s00431-018-3145-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

1.  Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2005-09-15

2.  "I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9.

Authors:  E Kissling; M Valenciano; Jm Falcao; A Larrauri; K Widgren; D Pitigoi; B Oroszi; B Nunes; C Savulescu; A Mazick; E Lupulescu; B Ciancio; A Moren
Journal:  Euro Surveill       Date:  2009-11-05

3.  Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan.

Authors:  Norio Sugaya; Yoshinao Takeuchi
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

4.  Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010-2014.

Authors:  Brendan Flannery; Sue B Reynolds; Lenee Blanton; Tammy A Santibanez; Alissa O'Halloran; Peng-Jun Lu; Jufu Chen; Ivo M Foppa; Paul Gargiullo; Joseph Bresee; James A Singleton; Alicia M Fry
Journal:  Pediatrics       Date:  2017-04-03       Impact factor: 7.124

5.  The test-negative design for estimating influenza vaccine effectiveness.

Authors:  Michael L Jackson; Jennifer C Nelson
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

6.  Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.

Authors:  Danuta M Skowronski; Gaston De Serres; Natasha S Crowcroft; Naveed Z Janjua; Nicole Boulianne; Travis S Hottes; Laura C Rosella; James A Dickinson; Rodica Gilca; Pam Sethi; Najwa Ouhoummane; Donald J Willison; Isabelle Rouleau; Martin Petric; Kevin Fonseca; Steven J Drews; Anuradha Rebbapragada; Hugues Charest; Marie-Eve Hamelin; Guy Boivin; Jennifer L Gardy; Yan Li; Trijntje L Kwindt; David M Patrick; Robert C Brunham
Journal:  PLoS Med       Date:  2010-04-06       Impact factor: 11.069

7.  Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine.

Authors:  Jessie R Chung; Brendan Flannery; Mark G Thompson; Manjusha Gaglani; Michael L Jackson; Arnold S Monto; Mary Patricia Nowalk; H Keipp Talbot; John J Treanor; Edward A Belongia; Kempapura Murthy; Lisa A Jackson; Joshua G Petrie; Richard K Zimmerman; Marie R Griffin; Huong Q McLean; Alicia M Fry
Journal:  Pediatrics       Date:  2016-01-05       Impact factor: 7.124

8.  Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season.

Authors:  Edward A Belongia; Burney A Kieke; James G Donahue; Robert T Greenlee; Amanda Balish; Angie Foust; Stephen Lindstrom; David K Shay
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

9.  Effectiveness of Trivalent Inactivated Influenza Vaccine in Children Estimated by a Test-Negative Case-Control Design Study Based on Influenza Rapid Diagnostic Test Results.

Authors:  Masayoshi Shinjoh; Norio Sugaya; Yoshio Yamaguchi; Yuka Tomidokoro; Shinichiro Sekiguchi; Keiko Mitamura; Motoko Fujino; Hiroyuki Shiro; Osamu Komiyama; Nobuhiko Taguchi; Yuji Nakata; Naoko Yoshida; Atsushi Narabayashi; Michiko Myokai; Masanori Sato; Munehiro Furuichi; Hiroaki Baba; Hisayo Fujita; Akihiro Sato; Ichiro Ookawara; Kenichiro Tsunematsu; Makoto Yoshida; Mio Kono; Fumie Tanaka; Chiharu Kawakami; Takahisa Kimiya; Takao Takahashi; Satoshi Iwata
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

10.  Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccine against laboratory-confirmed influenza in hospitalised children aged 6-59 months.

Authors:  Gabriela A Dixon; Hannah C Moore; Heath Kelly; Peter Jacoby; Dale Carcione; Simon Williams; David Smith; Anthony D Keil; Paul Van Buynder; Peter C Richmond
Journal:  Influenza Other Respir Viruses       Date:  2010-07       Impact factor: 4.380

View more
  4 in total

1.  Effectiveness of Partial and Full Influenza Vaccination Among Children Aged <9 Years in Hong Kong, 2011-2019.

Authors:  Huiying Chua; Susan S Chiu; Eunice L Y Chan; Shuo Feng; Mike Y W Kwan; Joshua S C Wong; J S Malik Peiris; Benjamin J Cowling
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

2.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

3.  Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season.

Authors:  Masayoshi Shinjoh; Norio Sugaya; Yoshio Yamaguchi; Ichiro Ookawara; Yuji Nakata; Atsushi Narabayashi; Munehiro Furuichi; Naoko Yoshida; Akinobu Kamei; Yuu Kuramochi; Akimichi Shibata; Motoko Shimoyamada; Hisataka Nakazaki; Naohiko Maejima; Erika Yuasa; Eriko Araki; Naonori Maeda; Takuma Ohnishi; Mitsuhiro Nishida; Nobuhiko Taguchi; Makoto Yoshida; Kenichiro Tsunematsu; Meiwa Shibata; Yasuhiro Hirano; Shinichiro Sekiguchi; Chiharu Kawakami; Keiko Mitamura; Takao Takahashi
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

4.  Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.

Authors:  Masayoshi Shinjoh; Munehiro Furuichi; Hisato Kobayashi; Yoshio Yamaguchi; Naonori Maeda; Mizuki Yaginuma; Ken Kobayashi; Taisuke Nogayama; Michiko Chiga; Mio Oshima; Yuu Kuramochi; Go Yamada; Atsushi Narabayashi; Ichiro Ookawara; Mitsuhiro Nishida; Kenichiro Tsunematsu; Isamu Kamimaki; Motoko Shimoyamada; Makoto Yoshida; Akimichi Shibata; Yuji Nakata; Nobuhiko Taguchi; Keiko Mitamura; Takao Takahashi
Journal:  Vaccine       Date:  2022-04-11       Impact factor: 4.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.